Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Pain
 More »

  • Pain Therapeutics
    London UNITED KINGDOM http://www.smi-online.co.uk/pharmaceuticals/uk/pain-therapeutics
    5-20-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Xenon Pharmaceuticals and Roche (Genentech) Agreement announced January 9, 2012 Strategic alliance designed to discover and develop companion diagnostics and compounds for pain. ...
    5-9-2013
  • Celgene, Concert in $300M+ Deuterium Drug Collaboration
    Also in Concert's pipeline are CTP-354 for spasticity and neuropathic pain; C-10068 for epilepsy and depression; D-Ivacaftor for cystic fibrosis and COPD; and D-Praziquantel, now ...
    5-6-2013
  • Migraines Linked to Gene Mutation
    Pain threshold, explains Dr. Ptácek, can be lowered in mice by the administration of ... lower threshold for nitroglycerin-induced peripheral pain than did normal mice. ...
    5-2-2013
  • Why Can't You Keep the Weight Off?
    This neurochemical system is involved in a variety of physiological processes including appetite, pain, mood, stress responses, and memory. Food consumption is controlled in part ...
    4-30-2013
  • Hormone Holds Promise for Replacing Insulin Injections
    ... partnerships with top-tier pharmaceutical and biotechnology companies in key therapeutic areas that include neuroscience, pain, metabolic diseases, oncology, and inflammation. ...
    4-26-2013
  • Pfizer, Alberta Renew Funding for Translational Research
    Priority areas for collaboration research included neuroscience, Alzheimer's Disease, neurodegeneration and other neurological diseases; pain and sensory disorders; immunology and ...
    4-25-2013
  • Merck & Co. Picks Up Exclusive Option on Xenon CV Drugs
    for acute coronary syndrome chest pain caused by coronary artery disease, and ... In addition to CV disorders, other medical areas of focus for the company include pain, ...
    4-17-2013
  • Exploring GPCRs as Therapeutic Targets
    Lefkowitz' former post-docs, Jonathan Violin, Ph.D., now head of biology at Trevena. He will discuss how Trevena is using receptor bias for clinical development of pain ...
    4-15-2013
  • Poland Invests in Biotech Infrastructure
    ... days and leg ulcers in 46 days, which Lemke claims is up to 40 percent quicker than those treated with other dressing types and he says patients report less pain during healing. ...
    4-15-2013
  • Personalized Medicine: The Societal Perspective
    ... Some patients will think a 10% chance to respond well to the treatment is a fair chance, while others will not find it worth the discomfort or pain. The patient will have to be ...
    4-8-2013
  • Biogen Idec Prepares to Launch 4th MS Drug
    ... The most common side effects associated with Tecfidera were flushing and gastrointestinal events such as diarrhea, nausea, and abdominal pain. Flushing symptoms usually began soon ...
    3-28-2013
  • Galena Buys Orexo's Pain Drug for $10M+
    of fentanyl, an opioid, and is indicated for the management of breakthrough pain. ... and in addition milestones and royalty payments. Galena Buys Orexo's Pain Drug for $10M+
    3-18-2013
  • Medicine: Getting Personal
    ... and reinjection of a patient's stem cells to treat joint, muscle, tendon, or bone pain; Regenexx argued the treatment is a procedure, while FDA contended it is a drug. 9. ...
    3-15-2013
  • People in the News
    Ph.D. , to regulatory scientist I, and Kasey Lawrence to technology specialist...Pain Therapeutics appointed Saira Ramasastry to its board of directors as an independent director. ...
    3-15-2013
  • More »

    Journal Articles

  • Unknown Fever and Back Pain Caused by Bartonella henselae in...
    Jen-Wei Lin, Chih-Ming Chen, Chao-Chin Chang
    Vector-Borne and Zoonotic Diseases
    Unknown Fever and Back Pain Caused by Bartonella henselae in a Veterinarian After a Needle ... of cat-scratch disease, rarely causes back pain and is considered to be transmitted ...
  • Osteoarthritis Treated with Mesenchymal Stem Cells on Hyaluronan...
    Brunella Grigolo, Gina Lisignoli, Giovanna Desando, Carola Cavallo, Emanuele Marconi, Matilde Tschon, Gianluca Giavaresi, Milena Fini, Roberto Giardino, Andrea Facchini
    Tissue Engineering, Part C: Methods
    Up to now, despite the increasing number of patients with OA, treatments to manage the disease remain symptomatic, designed to control pain, and improve function and quality of ...
  • Exploring Therapeutic Alliance with an Internet-Based Self-Management...
    Meghan White, Jennifer N. Stinson, Patricia Lingley-Pottie, Patrick J. McGrath, Navreet Gill, Abi Vijenthira
    Telemedicine and e-Health
    face-to-face data and pediatric distance treatment data. Therapeutic alliance scores were also found to be correlated with improved treatment outcomes (decreased reported pain).
  • Wound Contraction Is Significantly Reduced by the Use of Microcarriers...
    Mohamed Eldardiri, Yella Martin, Judy Roxburgh, Diana J. Lawrence-Watt, Justin R. Sharpe
    Tissue Engineering, Part A
    This can lead to significant contracture formation, especially in large full-thickness injuries, causing lack of mobility and pain. Contraction is reduced when wounds are treated ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll